Skip to Main Content

Paper Details

Inactivation of PP2A by a recurrent mutation drives resistance to MEK inhibitors.
Oncogene
24
2020
A, Arg, C subunit, MAPK, MEK, PP2A, PP2A A scaffold, PP2A A scaffolding subunit, PP2A A/, PP2A holoenzyme, PP2A regulatory subunits, PPP2R1A, R183W, RAS, RAS-mutant, RAS-mutant cells, cancer, serine, serine/threonine Protein Phosphatase 2A, threonine, transformed cells, tumor, wild-type A
Author NameAffiliation
Caitlin M O'ConnorCase Western Reserve University
Daniel LeonardCase Western Reserve University
Danica D WiredjaCenter for Proteomics and Bioinformatics, Case Western Reserve University
Rita A AvelarUniversity of Michigan ann arbor
Zhizhi WangUniversity of Washington
Daniela SchlatzerCenter for Proteomics and Bioinformatics, Case Western Reserve University
Jaya SangodkarUniversity of Michigan ann arbor
Jaya SangodkarUniversity of Michigan ann arbor
Anne-Claude GingrasLunenfeld-Tanenbaum Research Institute
Anne-Claude GingrasUniversity of Toronto
Wenqing XuUniversity of Washington
Analisa DiFeoUniversity of Michigan ann arbor
Analisa DiFeoUniversity of Michigan ann arbor
Analisa DiFeoRogel Cancer Center, University of Michigan ann arbor
David L BrautiganUniversity of Virginia
Shozeb HaiderDepartment of Pharmaceutical and Biological Chemistry, University College London
Goutham NarlaUniversity of Michigan ann arbor
Goutham NarlaRogel Cancer Center, University of Michigan ann arbor
Goutham NarlaUniversity of Michigan ann arbor
Goutham NarlaRogel Cancer Center, University of Michigan ann arbor
  • 1 - 20

Datasets

Release 1.2